Biogen Idec In Retrospect: Shares Down 4.7% Since Downgraded One Week Ago (BIIB)

Standpoint Research downgraded Biogen Idec (NASDAQ:BIIB) from Buy to Hold a week ago. Biogen Idec shares are selling at $314.49, 4.7% below the $330.11 price point of one week...